Aktionsplan Galectin Therapeutics Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. weitere detailsIPO date | 2002-09-09 |
---|---|
ISIN | US3632252025 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://galectintherapeutics.com |
Цена ао | 2.37 |
Preisänderung pro Tag: | +32.17% (0.8701) |
---|---|
Preisänderung pro Woche: | +10.58% (1.04) |
Preisänderung pro Monat: | -59.44% (2.835) |
Preisänderung über 3 Monate: | -57.56% (2.71) |
Preisänderung über sechs Monate: | -49.56% (2.28) |
Preisänderung pro Jahr: | -30.72% (1.66) |
Preisänderung über 3 Jahre: | -50.43% (2.32) |
Preisänderung über 5 Jahre: | -62.05% (3.03) |
Preisänderung über 10 Jahre: | 0% (1.15) |
Preisänderung seit Jahresbeginn: | -60.21% (2.89) |
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
Institutionen | Volumen | Aktie, % |
---|---|---|
Vanguard Group Inc | 1941854 | 3.14 |
Osaic Holdings Inc | 1251048 | 2.02 |
Blackrock Inc. | 715351 | 1.16 |
Geode Capital Management, LLC | 514416 | 0.83 |
Geneos Wealth Management, Inc. | 412650 | 0.67 |
Atria Wealth Solutions, Inc. | 249800 | 0.4 |
Morgan Stanley | 185147 | 0.3 |
Wealthspire Advisors, LLC | 183862 | 0.3 |
State Street Corporation | 161440 | 0.26 |
Cambridge Investment Research Advisors Inc. | 126581 | 0.2 |
ETF | Aktie, % | Rentabilität für das Jahr, % | Dividenden, % |
---|---|---|---|
iShares Micro-Cap ETF | 0.01442 | 17.09 | 1.54048 |
![]() |
0.00247 | 38.04 | 0.6026 |
![]() |
0.00122 | 89.82 | 1.47873 |
ProShares Hedge Replication ETF | 0.00034 | 5.92 | 1.47892 |
Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
Vanguard Russell 2000 Growth ETF | 0 | 23.05 | 0.60264 |
0 | 31.85 | 1.2 |
Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
---|---|---|---|
Mr. Joel Lewis | President, CEO & Director | 907.72k | 1970 (55 Jahre) |
Mr. Jack W. Callicutt CPA | CFO, Treasurer & Corporate Secretary | 521.47k | 1967 (58 Jahre) |
Robert Tritt | General Counsel | N/A | |
Mr. Jeff Katstra | Head of CMC & Pharmaceutical Development | N/A | |
Ms. Beth Knowles | Executive Assistant & Officer Manager | N/A | |
Mr. Khurram Jamil M.D. | Chief Medical Officer |
Adresse: United States, Norcross. GA, 4960 Peachtree Industrial Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://galectintherapeutics.com
Webseite: https://galectintherapeutics.com